SLNO Soleno Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
11:13
Jun 17
Jun 17
Author reflects on a prior bullish call on biotech bottom and specific catalysts like QURE.
Author reflects on a prior bullish call on biotech bottom and specific catalysts like QURE approval and ABVX acquisition, but the tweet is a retrospective check-in rather than a fresh forward position.
15:42
Jun 08
Jun 08
Author references flashbacks to a previous SLNO price move.
Author references flashbacks to a previous SLNO price move, implying a similar pattern but without stating a current position or forward call.
LOW
15:09
May 29
May 29
The author highlights Chris Staral's past holdings and return under Triple Helix.
The author highlights Chris Staral's past holdings and return under Triple Helix, but this is a historical research summary and watchlist, not an active position or forward call.
LOW
15:26
May 27
May 27
The author expresses frustration with SLNO's persistent decline but confidently predicts it.
The author expresses frustration with SLNO's persistent decline but confidently predicts it will eventually have a breakout day, drawing a bullish parallel to a past pattern.
15:07
Apr 09
Apr 09
Adding capital to an existing, high-conviction long position in SLNO rather than seeking new.
Adding capital to an existing, high-conviction long position in SLNO rather than seeking new setups.
HIGH
01:26
Apr 07
Apr 07
Buyout announcement creates a clear, immediate arbitrage opportunity to go long SLNO as it will.
Buyout announcement creates a clear, immediate arbitrage opportunity to go long SLNO as it will trade up toward the acquisition price.
MED
23:07
Mar 31
Mar 31
The user expresses relief or resilience regarding their positions in ABVX and SLNO.
15:02
Mar 31
Mar 31
The author suggests SLNO is poised for a potential breakout due to its association.
The author suggests SLNO is poised for a potential breakout due to its association with successful M&A activity.
14:10
Mar 31
Mar 31
Author expects SLNO to be acquired next (following APLS deal) because it is the only remaining.
Author expects SLNO to be acquired next (following APLS deal) because it is the only remaining drug option in its niche after a competitor's drug was halted for safety.
HIGH
14:07
Mar 31
Mar 31
Following the APLS buyout, SLNO is a prime acquisition target with a monopoly in its indication.
Following the APLS buyout, SLNO is a prime acquisition target with a monopoly in its indication after a competitor's drug was halted, trading at a low enterprise value relative to its projected free cash flow.
HIGH
17:20
Mar 27
Mar 27
The trader is aggressively selling puts on ABVX and SLNO, indicating a bullish outlook.
16:51
Mar 24
Mar 24
The author is aggressively accumulating shares of SLNO at current price levels.
18:29
Mar 15
Mar 15
The author provides a routine portfolio update detailing additions, reductions.
The author provides a routine portfolio update detailing additions, reductions, and closures across various biotech stocks.
05:40
Feb 26
Feb 26
Shorting the stock based on a significant downward price target revision from a sell-side.
Shorting the stock based on a significant downward price target revision from a sell-side analyst, implying a negative change in the fundamental outlook.
MED
About SLNO Analyst Coverage
Buzzberg tracks SLNO (Soleno Therapeutics, Inc. Common Stock) across 4 sources. 9 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (64%). 14 total trade ideas tracked. Latest voices: seedy19tron, BarbarianCap, jam_croissant.